In this regard, Solitomab (MT110, AMG 110), an EpCAM/CD3-bispecific single-chain antibody, is able to bind polyclonal CD8+ and CD4+ T cells and activate them, addressing against EpCAM-expressing tumor cells [71]. Here, EPCAM is linked to neoplasm.